6 results
The purpose of this Clinical investigation is to further evaluate the safety and performance of the EnligHTN* Renal Denervation System in the treatment of patients with uncontrolled hypertension.
The primary objective of this trial is as follows:• To determine the pharmacokinetics of anidulafungin administered to obese patients with a BMI >= 40 kg/m2. The secondary objective of this trial is as follows:• To simulate pharmacokinetics…
The aim of this post-CE study is to collect data on the effects of renal sympathetic denervation on the insulin resistance and muscle sympathetic nerve activity (MSNA) in patients with metabolic syndrome and associated hypertension.
To determine the effects of renal sympathetic denervation on insulin resistance and muscle sympathetic nerve activity (MSNA) in patients with metabolic syndrome at 3 months after renal denervation.
To investigate the correlation of pharmacokinetic parameters of anidulafungin with markers for disease severity and plasma protein levels.
The primary objective of this trial is as follows:• To determine the pharmacokinetics of anidulafungin given once in every 2 days (q48h) or once in every 3 days (q72h) to patients undergoing an allogeneic haematopoietic stem cell transplant…